Mansi Malik

Mansi Malik

Mansi Malik
Scientist
mansi.malik@tigs.res.in

Education

  • MBA, Rady School of Management, University of California San Diego, 2019
  • PhD Applied Biology, University of Mumbai, 2018
  • MSc. Biotechnology, University of Mumbai, 2008-2010

Experience

  • Post-doctoral researcher, Section of Cell and Developmental Biology, Division of Biological Sciences, University of California, San Diego, USA, 2018-2020
  • Research Officer, Molecular Diagnostics, Panacea Care Diagnostics, 2017
  • Senior Research Fellow-ICMR Haffkine Institute for Training, Research and Testing, 2013-2017
  • Junior Research Fellow, 2011-2013
  • Research Intern, NIRRH, Mumbai, 2009

Expertise

  • Public health surveillance
  • Parasite biology and evolution
  • Mosquito biology and genetics
  • Biomanipulation of mosquitoes via microinjections
  • Crispr-Cas gene editing

Areas of Interest

  • Vector borne infectious disease surveillance and control strategies
  • Mosquito immunity to transmissible parasitic/viral infections
  • Drug repurposing strategies
  • Host and parasite interactions; evolution and development
  • Biomanipulation of important insect vectors

Honors and Awards

  • Sanford Burnham Prebys Leadership Development Program, San Diego, California, USA 2020-2021
  • Entrepreneurship Development Program, School of Global Policy and Strategy, University of California, San Diego, USA 2019-2020
  • Best Participant Award, EMBO-Malaria Genomics and Public Health Madurai, India 2017

Publications

  • Mansi Malik, Parvathy Vijayan, Deepak K. Jagannath, Rakesh K. Mishra, Anirudha Lakshminarasimhan. Sofosbuvir and its tri-phosphate metabolite inhibit the RNA- dependent RNA polymerase activity of non-structural protein 5 from the Kyasanur forest disease virus, Biochemical and Biophysical Research Communications, Volume 641,2023, pp 50-56, December 2022 DOI: https://doi.org/10.1016/j.bbrc.2022.12.023
  • Evaluation of Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA vaccine comprising Envelope Domain III in Mice, March 2017, Iranian Journal of Medical Sciences.